Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Position Raised by TD Asset Management Inc

Key Points

• TD Asset Management Inc increased its stake in Agios Pharmaceuticals by 7.5%, acquiring an additional 12,400 shares, bringing its total ownership to 178,072 shares valued at approximately $5.2 million.
• Several large investors, including Vanguard Group and Deutsche Bank AG, have also adjusted their positions in Agios Pharmaceuticals, demonstrating renewed interest in the company.
• Agios Pharmaceuticals reported a quarterly loss of $1.93 EPS, falling short of the expected ($1.74 EPS), despite surpassing revenue expectations with $12.5 million in revenue.

TD Asset Management Inc boosted its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 7.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 178,072 shares of the biopharmaceutical company's stock after buying an additional 12,400 shares during the quarter. TD Asset Management Inc owned 0.31% of Agios Pharmaceuticals worth $5,218,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in Agios Pharmaceuticals during the 4th quarter valued at about $39,000. CWM LLC grew its position in shares of Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 996 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in shares of Agios Pharmaceuticals by 7.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after acquiring an additional 394 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Agios Pharmaceuticals by 9,296.6% in the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock worth $240,000 after acquiring an additional 8,088 shares during the last quarter.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,770 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares in the company, valued at approximately $876,131.88. This represents a 9.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sarah Gheuens sold 11,914 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the sale, the insider directly owned 61,271 shares of the company's stock, valued at $2,327,685.29. The trade was a 16.28% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,363 shares of company stock worth $1,619,654. Corporate insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Trading Up 2.5%

NASDAQ:AGIO traded up $0.92 on Wednesday, hitting $37.13. 477,341 shares of the stock were exchanged, compared to its average volume of 718,594. The stock has a market cap of $2.16 billion, a PE ratio of 3.37 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock has a fifty day moving average of $35.93 and a 200-day moving average of $32.62.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The business had revenue of $12.50 million during the quarter, compared to analysts' expectations of $9.46 million. As a group, analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on AGIO shares. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Scotiabank cut their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research report on Monday, July 28th. Finally, Bank of America decreased their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.